{"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"61"}],"units":"Participants"}],"groups":[{"description":"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Arm I (Bortezomib+Irinotecan)"},{"description":"Patients receive bortezomib (PS-341) 1.3 mg/m2 IV over 3-5 seconds twice weekly on days 1, 4, 8 and 11 followed by one week of rest. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may cross over to arm I (bortezomib + irinotecan).","id":"BG001","title":"Arm II (Bortezomib)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"36","upperLimit":"85","value":"61"},{"groupId":"BG001","lowerLimit":"45","upperLimit":"78","value":"61"},{"groupId":"BG002","lowerLimit":"36","upperLimit":"85","value":"61"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"9"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"52"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"61"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}